Recruiting Erectile Dysfunction Studies in Bakersfield
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic ma...
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breat...
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...
About Erectile Dysfunction Clinical Trials in Bakersfield
Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.
There are currently 6 erectile dysfunction clinical trials recruiting participants in Bakersfield, CA. These studies are seeking a combined 5,546 participants. Research is being sponsored by Merck Sharp & Dohme LLC, EyeBiotech Ltd., Hoffmann-La Roche and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Erectile Dysfunction Clinical Trials in Bakersfield — FAQ
Are there erectile dysfunction clinical trials in Bakersfield?
Yes, there are 6 erectile dysfunction clinical trials currently recruiting in Bakersfield, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Bakersfield?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Bakersfield research site will contact you about next steps.
Are clinical trials in Bakersfield free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Bakersfield studies also compensate for your time and travel.
What erectile dysfunction treatments are being tested?
The 6 active trials in Bakersfield are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.
Data updated June 2, 2026 from ClinicalTrials.gov